A Randomized, Blinded, Phase 2 Dose-Ranging Study Of BMS-936558 (MDX-1106) In Subjects With Progressive, Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
收藏DataCite Commons2026-01-28 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012705/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.
提供机构：
Vivli
创建时间：
2026-01-28
